NEFL and amyotrophic lateral sclerosis: Furthermore, our results have implications for the clinical use of NfL and pTau serum levels as biomarkers for neurodegeneration and dementia such as AD, frontotemporal lobe degeneration, and amyotrophic lateral sclerosis.